key: cord-0798314-hz83yhty
authors: Chiu, Hsien-Yi; Chang Liao, Nien-Feng; Lin, Yu; Huang, Yu-Huei
title: Perception of the threat, mental health burden, and healthcare-seeking behavior change among psoriasis patients during the COVID-19 pandemic
date: 2021-12-09
journal: PLoS One
DOI: 10.1371/journal.pone.0259852
sha: 9abe759b04357136f31ce69d7b5cd06ecc01a335
doc_id: 798314
cord_uid: hz83yhty

This study aimed to investigate the perceived threat, mental health outcomes, behavior changes, and associated predictors among psoriasis patients during the COVID-19 pandemic. The COVID-19 has been known to increase the health risks of patients with psoriasis owing to patients’ immune dysregulation, comorbidities, and immunosuppressive drug use. A total of 423 psoriasis patients not infected with COVID-19 was recruited from the Department of Dermatology, National Taiwan University Hospital Hsin-Chu Branch, Chang Gung Memorial Hospital, and China Medical University Hospital from May 2020 to July 2020. A self-administered questionnaire was used to evaluate the perceived threat, mental health, and psychological impact on psoriasis patients using the Perceived COVID-19-Related Risk Scale score for Psoriasis (PCRSP), depression, anxiety, insomnia, and stress-associated symptoms (DAISS) scales, and Impact of Event Scale-Revised (IES-R), respectively. Over 94% of 423 patients with psoriasis perceived threat to be ≥ 1 due to COVID-19; 18% of the patients experienced psychological symptoms more frequently ≥ 1, and 22% perceived psychological impact during the pandemic to be ≥ 1. Multivariable linear regression showed that the higher psoriasis severity and comorbidities were significantly associated with higher PCRSP, DAISS, and IES-R scores. The requirement for a prolonged prescription and canceling or deferring clinic visits for psoriasis treatment among patients are the two most common healthcare-seeking behavior changes during the COVID-19 pandemic. Psoriasis patients who perceived a higher COVID-19 threat were more likely to require a prolonged prescription and have their clinic visits canceled or deferred. Surveillance of the psychological consequences in psoriasis patients due to COVID-19 must be implemented to avoid psychological consequences and inappropriate treatment delays or withdrawal.

a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

Patients' perceptions of the COVID-19 threat were measured using 13 items (S1 Table) based on a five-point Likert rating scale ranging from 1 (not worried at all) to 5 (very worried). The responses on these items were summed to produce the Perceived COVID-19-Related Risk Scale score for Psoriasis (PCRSP), which ranged from 13 to 85. In addition, participants were asked to choose the top three items of their most concern. Regarding mental health, patients were asked whether they experienced more depression, anxiety, insomnia, and stress-associated symptoms (DAISS) after the COVID-19 than before the outbreak on a five-point scale (from "1 = strongly disagree" to "5 = strongly agree") (S1 Table) . Moreover, the psychological impact of COVID-19 was measured using the 22-item Impact of Event Scale-Revised (IES-R; range, 0-88), which was well-validated in the Chinese population to determine the extent of psychological distress after exposure to a public health crisis, such as COVID-19 [24, 25] . The changes in healthcare-seeking behavior and therapy adherence during the COVID-19 pandemic were assessed using seven questions. In S1 Table, these questions inquired whether patients had adopted the prespecified behaviors more frequently at the time of the survey using a five-point Likert rating scale ranging from 1 (strongly disagreed) to 5 (strongly agree) as compared with behaviors adopted in the pre-COVID-19 period. Items in these questionnaires except the IES-R were chosen and modified based on the following: a review of the published literature investigating the impact of COVID-19 [26], Severe Acute Respiratory Syndrome (SARS) [16] , Middle East Respiratory Syndrome [27] , avian influenza pandemics [28] , and consultation with patients and clinical experts. Information about COVID-19-associated quarantined/isolation and psoriasis disease was collected using a questionnaire and/or chart review.

The content validity of PCRSP and DAISS was assessed by seven experts who rated the relevance of each question/item in the questionnaire on a scale of 1 to 4, and the results were presented as the Item Content Validity Index (I-CVI), as the average I-CVIs for all the items in the questionnaire (S-CVI/Ave), and total agreement [29, 30] . Internal consistency and the testretest reliability of the PCRSP and DAISS were evaluated using Cronbach's coefficient alpha (α > 0.70 is considered to be a good internal consistency) [31] . The intraclass correlation coefficients (ICC) are widely used for the reliability index. ICC � 0.6 is considered good reliability [32] . We also evaluated the correlations between these scales using Spearman's correlation coefficients (strong: rho � 0.5, moderate: 0.30 < rho < 0.49, weak: 0.10 < rho < 0.29) [33] to ensure convergent validity. Comparisons between two or more groups were conducted using the Mann-Whitney U test and the Kruskal-Wallis test for continuous variables and the chisquared test or Fisher's exact test for discrete variables. In subgroup analysis, patients were groups using the baseline psoriasis area and severity index (PASI) score, as follows: < 12, 12 � PASI < 20, or PASI � 20 [34] . Multivariable linear regression models were used to determine potential risk factors for PCRSP, DAISS, and IES-R. Independent variables included age, sex, body weight, the severity of psoriasis, family history of psoriasis, disease duration, comorbidities (including cardiovascular disease, diabetes, hyperlipidemia, and psychiatric disorder), psoriatic arthritis, friends or family member with quarantine experience, and treatment categories (biologics for cutaneous psoriasis, biologics for psoriatic arthritis, traditional antipsoriatic drugs or phototherapy and/or topical drugs only). The R software was used to estimate the target sample size. Since little preliminary data were used in this issue, we determined the sample size based on a previous study [35] that reported gender differences using the IES-R scale during the COVID-19 pandemic. We assumed that the mean (± SD) of the IES-R score for men was 8.56 (±11.86) and that of women was 14.11 (±14.09). For a male-to-female ratio of 3:1, a sample size of 420 patients is required to achieve a 95% power and 5% type 1 error.

Statistical analysis except the sample size estimation was performed using the SPSS 21 statistical package (IBM Corporation, Armonk, NY, USA). A p-value < 0.05 (two-tailed) was considered to be statistically significant.

The scores for S-CVI/Ave for PCRSP and DAISS were 0.98 and 1.00, respectively. The total agreement was 92.3% and 100%, respectively, which suggested the validity of the questionnaire content [36] . The construct validity of these scales was supported by a strong correlation between DAISS and IES-R (rho = 0.664, p < 0.001) and a moderate correlation between PCRCP and DAISS (rho = 0.416, p < 0.001) as well as PCRCP and IES-R (rho = 0.435, p < 0.001). For reliability, the internal consistency of the PCRCP and DAISS scale, measured by Cronbach's alpha coefficient, was 0.938 and 0.908, respectively. Both PCRCP (ICC = 0.907) and DAISS (ICC = 0.944) showed a good test-retest reliability.

Four hundred twenty-three psoriatic patients not infected with COVID-19 completed the survey. Table 1 shows the demographic and background characteristics of participants. Three Table) . Female patients with psoriasis, who had a comorbidity, had a psoriatic arthritis (PsA), had a psoriasis duration >15 years, had a higher PASI score at baseline (PASI �20), and whose friends or a family member had quarantine experience reported higher average PCRSP scores (aPCRSP) compared, respectively, with male patients (p = 0.004), had no comorbidity (p = 0.001), no PsA (p = 0.003), a duration �15 (p = 0.010), lower PASI score (PASI �20 vs. PASI <12, p = 0.001; PASI �20 vs. 12 � PASI < 20, p = 0.011), and without quarantine experience (p = 0.001). Moreover, patients who were treated with biologics reported higher average of aPCRSP score compared with those who were treated with phototherapy and/or topical drugs only (biologics for cutaneous psoriasis vs. phototherapy/topical, p = 0.005; biologics for PsA vs. phototherapy/topical, p = 0.002) (Fig 1) .

A considerable number of participants with psoriasis (17.7%) experienced at least one psychological symptom, more frequently (item score � 4) during the COVID-19 pandemic, which included depression (13.5%), stress (9.7%), insomnia (5.9%), and anxiety (5.4%) than before the outbreak. For IES-R, a total of 263 (21.7%) reported a psychological impact (IES-R � 24) [37] of COVID-19. Psoriasis patients with higher PASI score at baseline of (PASI � 20) and comorbidities scored higher in DAISS and IES-R than those with less severe disease and no comorbidities, respectively (PASI � 20 vs. PASI < 12, p = 0.012 for DAISS and p = 0.002 for IES-R; PASI � 20 vs. 12 � PASI < 20, p = 0.009 for DAISS and p = 0.011 for IES-R) (Fig 2) . Thirty-one percent of survey patients prefer switching to a long-term drug prescription for psoriasis or drugs that can decrease clinic visits for a long term during the COVID-19 pandemic (S3 Table) . Compared with patients who had a PCRSP < 3 and disease duration >15 years, those with aPCRSP � 3 (p = 0.045) and disease duration � 15 years (p = 0.005) were more likely to require a prolonged prescription. Thirteen percent of patients postponed, canceled, or reduced scheduled clinic visits for psoriasis treatment, particularly those whose friends or family members had a quarantine experience (p = 0.001) and those with aPCRSP � 3 (p = 0.044) (Fig 3) . Fewer than 5 percent of patients interrupted or discontinued with phototherapy, oral drugs, or biologics for psoriasis treatment and did not take medications for psoriasis according to their doctor's instructions or postponed healthcare-seeking behavior for other non-COVID-19 diseases owing to risks associated with COVID-19.

Multivariable linear regression showed that more severe psoriasis measured by PASI, comorbidities, female sex, duration of psoriasis >15 years, and friends or a family member with quarantine experience was significantly associated with a higher aPCRSP. Similarly, a higher PASI, comorbidity, and female sex were significantly associated with DAISS. A higher PASI and comorbidities were associated with a higher IES-R score ( Table 2 ).

The COVID-19 pandemic has brought the risks of physical illness or death from viral infection and unbearable psychological pressure [26] . The outcomes of a survey that evaluated the severity of the COVID-19 outbreak in China showed that approximately one-third of the participants reported moderate-to-severe anxiety, while more than half rated the psychological impact as moderate-to-severe [26] . Psoriasis is a systemic inflammatory disease characterized by immune dysregulation, and it is independently linked to a risk of serious infection [38] . Patients with psoriasis are more likely to face risks of comorbidities (such as hypertension, diabetes, and cardiovascular disease) [39] , associated with high COVID-19 fatality [13] . A significant body of research also indicates that type I interferon, TNF-α, B-cell released antibodies, and other cytokines play a significant role in the viral immune response that combats infection against viral pathogens and promotes clearance [40] . Considering the medication's mechanism, psoriatic patients, taking TNF-α inhibitors, abatacept (CTLA-4 inhibitor), and ustekinumab (IL-12/23 inhibitor), known to modulate and blunt Th1 responses [39] , are concerned about the possibility of increased susceptibility to COVID-19 infection. Therefore, facing this large-scale infectious outbreak, patients with psoriasis are theoretically vulnerable to the psychological impact caused by COVID-19. To support this notion, our results showed that 94.3% of patients with psoriasis perceived at least one threat caused by COVID-19, and 88.6% of patients with psoriasis perceived at least two threats caused by COVID-19. Friends or a family member with or without quarantine experience. � P < 0.05; �� P < 0.01, ��� P < 0.001. Comparisons between groups were performed using the Mann-Whitney U test except for the subgroups that were stratified by PASI and treatment modalities, assessed using the Kruskal-Wallis test.

https://doi.org/10.1371/journal.pone.0259852.g001 Moreover, psoriasis severity and duration, PsA, and comorbidities are vulnerability factors associated with patients' perception of the COVID-19 threat, as shown by PCRSP. Patients with more severe psoriasis and comorbidity also reported more psychological symptoms caused by COVID-19 as revealed by DAISS and IES-R scales. The reasons for these associations are not fully understood. However, a recent meta-analysis shows that chronic or severe physical illness is associated with an increased risk of mental disorders, which include anxiety disorder, depression, bipolar disorders, and schizophrenia [41] . Thus, it is reasonable to argue that the accumulated stress or burden associated with a serious underlying physical illness or comorbidities may intensify the perception of danger and increase an individual's lifetime vulnerability to mental disorder. A recent study found that higher levels of depression and anxiety are found in patients with severe psoriasis [42, 43] . Moreover, there is a significant correlation between psoriasis severity, perceived stress, and mood alterations [44, 45] . Patients with PsA also face a high risk of mental disorders, such as depression, which appears to be greater than patients with cutaneous psoriasis only [46] . Similar to the psychological burden caused by SARS [47, 48] , our regression analysis indicated that the female sex was an independent factor associated with a higher likelihood of reporting depression, anxiety, insomnia, and distress from the threat of COVID-19, as shown by PCRSP [49] . A growing body of evidence indicates that women are more vulnerable to most traumatic and disaster events and they face an increased risk of developing psychopathological consequences, such as psychiatric disorders [50] [51] [52] .

Compared with the percentage of patients who perceived a COVID-19 threat and psychological impact, the percentage of change in healthcare-seeking behaviors among psoriasis patients was less prominent in the present study. This was probably because our government initiated a rapid and effective strategy to combat the COVID-19 outbreak, using real-time surveillance for case identification, border control, and quarantine. The government also allocated anti-pandemic resources [53, 54] to mitigate the COVID-19 impact, prevent the breakdown of the medical care system, and maintain easy and safe access to health care. Our results revealed that a greater perception of a COVID-19-related threat was significantly associated with changes in healthcare-seeking behaviors. A higher proportion of canceling or deferring clinic visits by psoriasis patients was recorded by those who had friends or a family member with quarantine experience because of the fear of exposure to COVID-19. Previous studies also found that higher perceived risk, threat, or danger was related to protective or preventive behavior changes during the COVID-19 outbreak [55, 56] . The inverse association between the disease duration and a prolonged prescription was probable because patients with a longer disease duration were more likely to believe the benefits of regular assessment and treatment for psoriasis outweighed the potential risks caused by COVID-19. This study has some limitations. First, the Taiwanese population is the selected patient for clinical research, and it might be difficult to generalize the results to other ethnic groups in other regions. Second, information was collected quickly over a relatively few weeks because of the uncertainty associated with the disease under investigation. Thus, the possibility of selection bias may be possible.

In conclusion, we identified a major perception of threat and mental health burden among psoriasis patients during the COVID-19 outbreak. Over 94% of patients perceived at least one threat caused by COVID-19, and 18% of patients experienced � 1 psychological symptom more frequently, and 22% of patients experienced psychological impact during the pandemic. Patients with more severe psoriasis, comorbidity, and female sex face a higher risk of perceiving a greater threat and are more likely to experience psychological symptoms caused by COVID-19. The requirements for a prolonged prescription and reducing clinic visits for psoriasis treatment were the two most common healthcare-seeking behavior changes during the pandemic, significantly associated with patients' awareness of a threat due to COVID-19. Continuous surveillance of the psychological consequences caused by the COVID-19 pandemic in patients with psoriasis must be immediately implemented along with the provision of mental health support, particularly for vulnerable groups to mitigate the impact of the COVID-19 pandemic. 

World Health Organization Coronavirus Disease (COVID-19) Dashboard

Real estimates of mortality following COVID-19 infection

The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis

Moderate and severe plaque psoriasis: cost-of-illness study in Italy

The psychological impact of the coronavirus disease pandemic on hospital

Instrument review: Getting the most from a panel of experts

Psychometric properties of the Impact of Event Scale-Revised

Risk of hospitalization and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink

Psoriasis in Taiwan: From epidemiology to new treatments

Coronavirus infections and immune responses

Co-morbidities of mental disorders and chronic physical diseases in developing and emerging countries: a meta-analysis

Psoriasis: depression, anxiety, smoking, and drinking habits

Psoriasis and Depression: A Comprehensive Review for Clinicians

Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis

The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study

Depression and anxiety in psoriatic disease: prevalence and associated factors

Stress and psychological distress among SARS survivors 1 year after the outbreak

Psychological distress and negative appraisals in survivors of severe acute respiratory syndrome (SARS)

Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease

Posttraumatic stress disorder in adults: impact, comorbidity, risk factors, and treatment

Mental health consequences of disasters

Prevalence of Depression in the Community from 30 Countries between

Initial rapid and proactive response for the COVID-19 outbreak-Taiwan's experience

Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing